News

An immune cell subset called innate lymphoid cells (ILC3s) protects against colorectal cancer, in part by helping to maintain a healthy dialogue between the immune system and gut microbes, according to a new study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Weill Cornell Medicine has been awarded a five-year, $28.5 million Martin Delaney Collaboratory grant from the National Institutes of Health to lead a multi-institutional effort aimed at finding a cure for HIV.

The degree to which the brain’s wiring aligns with its patterns of activity can vary with sex and age, and may be genetic, suggests a study published by Weill Cornell Medicine investigators. 

The autoimmune disease lupus may be triggered by a defective process in the development of red blood cells.

A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago.

A powerful immune-suppressing molecule produced by the body may hold the key to better treatments for autoimmune and inflammatory diseases, as well as for some cancers, according to a study by researchers at Weill Cornell Medicine and the University of Perugia.

A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led by scientists at Weill Cornell Medicine, NewYork-Presbyterian and Heidelberg University Hospital.

The specialized endothelial cells that line the blood vessels in the lung may hold the key to treating the common and often-fatal lung disease emphysema, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Weill Cornell Medicine’s Office of Diversity and Inclusion has been recognized as a Diversity Champion by Crain’s New York Business as part of its first annual Excellence in Diversity and Inclusion Awards, announced July 15.

Despite overwhelming evidence that the benefits of the COVID-19 vaccine outweigh the risks, and that the chances of dying from the coronavirus far exceed those of having an adverse reaction to the shot, reports of rare, (fewer than one in a million) post-vaccine blood clots may have you reconsidering vaccination.

Treatment with a ready-made preparation of human immune cells helps prevent infections in people whose immune systems are temporarily weakened by leukemia treatment.

Growth impairment, a common complication of Crohn’s disease in children, occurs more often in males than females, but the reasons are unclear. Now, a physician-scientist from Weill Cornell Medicine and NewYork-Presbyterian and colleagues at eight other centers have found that factors associated with statural growth differ by sex.

The pandemic is taking a toll on mental health. Fear of illness, as well as loss of income, housing, or schooling have left many people anxious, lonely, and depressed. The toll may be especially great among BIPOC (Black, Indigenous, People of Color) communities, where social and economic disenfranchisement and health and healthcare disparities contribute to higher levels of anxiety, depression, suicidal tendencies, post-traumatic stress, and other mental health disorders. 

Black patients who have chronic liver failure, also known as end stage liver disease (ESLD), are less likely to be placed on a waiting list for a life-saving liver transplant than other racial and ethnic groups, according to a study of national databases by investigators at Weill Cornell Medicine, NewYork-Presbyterian and Columbia University Vagelos College of Physicians and Surgeons.

The genetic changes that underlie an especially lethal type of prostate cancer have been revealed in a new study by investigators at Weill Cornell Medicine. Learning more about what causes this type of cancer, called neuroendocrine prostate cancer (NEPC), could lead to new approaches for treating it.

A protein called Them1 prevents fat burning in cells by blocking access to the fuel source, according to preclinical research by Weill Cornell Medicine, NewYork-Presbyterian and Harvard Medical School/Beth Israel Deaconess Medical Center investigators.

C2i Genomics, the spinout company to commercialize a super-sensitive cancer blood test developed by scientists at the New York Genome Center (NYGC) and Weill Cornell Medicine, has been named a finalist for The Spinoff Prize 2021. The announcement of this news and a profile of C2i Genomics was published in Nature today.

A tool to evaluate potential transplant candidates that looks at tumor marker levels in the blood can help predict which liver cancer patients are most likely to have their disease remain under control after receiving a transplant, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Cornell Atkinson has awarded eleven Academic Venture Fund (AVF) seed grants for research by 40 faculty researchers representing eight Cornell colleges and 19 academic departments. Dr. Nathaniel Hupert, associate professor of population health sciences, is an awardee.